EIT Emerging Implant Technologies GmbH, a Tuttlingen, Germany-based 3D printing specialist, received an investment from SHS Gesellschaft für Beteiligungsmanagement mbH. The news was confirmed on September 22.
3D Printed Implants
3D printing technology has been used to manufacture biocompatible implants in various areas. We’ve reported South Korean university developed a new biodegradable 3D printing material to reduce complications and to accelerate the regeneration of natural tissue. A new procedure using a 3D printed titanium implant turns out to save people suffering disfigurement from jaw tumours.
Cellular and porous implants of biocompatible titanium is indeed more advantageous than traditionally produced implants because they mimic the structure and stiffness of natural bone material more accurately. Besides, biocompatible implants could in turn promote bone ingrowth following fusion operations to achieve better clinical results and reduce complication rates. In addition to this, the implants can be fitted on a patient-specific basis, which serves to increase the contact surface and reduce future risks.
“Our EIT Cellular Titanium implants provide the answer to current challenges in implant design and choice of materials as well the extreme cost pressure in medical technology. The additive manufacturing technology allows us to tackle existing problems with new solutions. Thus we can improve the benefits for patients without increasing costs, which is a clear competitive advantage. This ensures a high level of patient satisfaction and excellent clinical results. We are looking forward to pushing ahead with our international growth, especially in the United States, and our product development with our new partner SHS.” (Guntmar Eisen, founder and CEO of EIT)
“EIT’s 3D-printed spine implants have already proven their superior functionality many times in practical applications, thus promoting EIT’s growth. EIT Emerging Implant Technologies’ management team is experienced and successful in the field of spine surgery. As a medical technology investor, we look forward to supporting them on their path to increased growth.” (Dr. Bernhard Schirmers, Managing Partner at SHS Gesellschaft für Beteiligungsmanagement.)
Funds Used For Innovative Products
EIT intends to use the funds for international growth and development of its innovative products.
“With SHS, EIT is gaining a shareholder with extensive experience in this industry. Together we can enter the next stage of EIT’s growth. This includes development of the company’s innovative product portfolio as well as entering new countries”. (Guy Selbherr, Managing Director of MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg)
With a total volume of 125 million euro, the fourth SHS fund is focusing on expansion financing, changes in shareholder structures and successor situations. The Tübingen based investor is planning further acquisitions and investments in the fast-growing medical technology and life-science industries in Germany, Austria and Switzerland in the months ahead.
Feature Image: EIT Emerging Implant Technologies